**Source URL:** https://medicines.health.europa.eu/veterinary/en/60000005345

# Linco-Spectin 100 222 mg/g - 444.7 mg/g Powder for use in drinking water



- Spectinomycin sulfate
- Lincomycin hydrochloride

## Product identification

#### **Medicine name:**

Linco-Spectin 100 222 mg/g - 444.7 mg/g Powder for use in drinking water LINCO-SPECTIN 100, 222/444,7 MG/G POUDRE POUR ADMINISTRATION DANS L'EAU DE BOISSON POUR PORCINS ET POULETS

#### **Active substance:**

Spectinomycin sulfate

Lincomycin hydrochloride

# Target species:

Pig

Chicken

#### Route of administration:

Oral use

## **Product details**

## **Active substance and strength:**

Spectinomycin sulfate 575.90 milligram(s) / 1.00 gram(s)

Lincomycin hydrochloride 241.90 milligram(s) / 1.00 gram(s)

#### **Pharmaceutical form:**

Powder for use in drinking water

## Withdrawal period by route of administration:

## Oral use:

Pig

- Meat and offal. no withdrawal period

0 days; Animals must not be slaughtered for human consumption during treatment.

# Anatomical therapeutic chemical veterinary (ATCvet) codes:

QJ01FF52

# Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

#### **Authorisation status:**

Valid

#### **Authorised in:**

France

## Package description:

Linco-Spectin 100 222 mg/g - 444.7 mg/g pwdr. for drinking water 1.5 kg Linco-Spectin 100 222 mg/g - 444.7 mg/g pwdr. for drinking water 150 g

# Additional information

## **Entitlement type:**

Marketing Authorisation

## Legal basis of product authorisation:

Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)

## Marketing authorisation holder:

Phibro Animal Health (Poland) Sp. z o.o.

## Marketing authorisation date:

21/07/1992

## Manufacturing sites for batch release:

Zoetis Belgium

## **Responsible authority:**

French Agency For Food, Environmental And Occupational Health & Safety

### **Authorisation number:**

FR/V/8295078 3/1992

# Date of authorisation status change:

21/07/2012

#### Reference member state:

Belgium

#### **Procedure number:**

BE/V/0029/001

#### **Concerned member states:**

Austria Cyprus Czechia Denmark Estonia France Germany Greece Hungary Ireland Italy Latvia Lithuania Luxembourg Poland Portugal Slovakia Spain United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

# **Documents**

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

Package Leaflet and Labelling

This document does not exist in this language (English). You can find it in another language below.